Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study

Morales-Núñez, José Javier; García‐Chagollán, Mariel; Muñoz‐Valle, José Francisco; Díaz-Pérez, Saúl Alberto; Torres-Hernández, Paola Carolina; Rodríguez-Reyes, Sarai Citlalic; Santoscoy‐Ascencio, Guillermo; Quevedo, José Julio Sierra García de; Hernández‐Bello, Jorge

doi:10.2147/jir.s374304

Cited by 4 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, further studies and monitoring of populational antibody levels and transmission rate are still required. Interestingly, a cohort study focused on the differences in B cell subpopulations between vaccinated and naturally infected cases has shown that the memory B cell has a higher level in naturally infected individuals compared to vaccinated populations [11]. Hence, the findings indicate the differences between the immunological memory generated via vaccinations and natural infections, which means there are still gaps for further improvements in vaccine design which would mimic a more realistic natural infection, and hence a better immune response.…”

Section: The Duration Of Sars-cov-2 Acquired Immunitymentioning

confidence: 99%

The failure to establish herd immunity against SARS-CoV-2

Cui

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

The current COVID-19 pandemic is undoubtedly one of the most severe global healthcare crises in the 21 st century. The traditional view on terminating a pandemic is establishing herd immunity via natural infections or vaccinations. However, this strategy might not be appropriate against SARS-CoV-2 due to many uncontrollable factors. This review has summarised several newest primary research and clinical studies to evaluate the reasons behind the failure of establishing this indirect protection with some alternative insights regarding future disease control. The review has found that variables such as the duration of humoral immunity against SARS-CoV-2, vaccines' ability to cut off the transmission, and the continuous emergence of immune evasive variants are vital contributors to the failed herd immunity establishment. Therefore, the overdependence on vaccination during the pandemic will not only waste valuable time and resources on disease containment but also creates this false illusion which dampens the public's alertness to the disease and amplifies the pandemic's impacts on world healthcare systems and economics. As a result, the traditional disease control policies, such as lockdown and quarantines, are as vital as vaccination for future infectious disease containment and pandemic management. It is the combination of both strategies that contribute to the establishment of herd immunity and pandemic termination.

show abstract

Section: The Duration Of Sars-cov-2 Acquired Immunitymentioning

confidence: 99%

The failure to establish herd immunity against SARS-CoV-2

Cui

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

show abstract

The Effect of SARS-CoV-2 Vaccination on B-Cell Phenotype in Systemic Sclerosis Patients

Pellicano

Colalillo

Basile

et al. 2022

JPM

View full text Add to dashboard Cite

Objective: to assess the influence of SARS-CoV-2 mRNA vaccine on B-cell phenotypes in systemic sclerosis (SSc). Methods: peripheral blood B-cell subpopulations were evaluated before (t1) and 3 months (t3) after the second dose of vaccine in 28 SSc patients. Peripheral blood B-cell subpopulations were evaluated in 21 healthy controls (HCs) only at t1. Anti-spike IgG levels were evaluated at t3 in both cohorts. Results: SSc patients presented higher naive, double-negative, and CD21low B cells compared to HCs. IgM-memory and switched-memory B cells were lower in SSc patients than HCs. No differences in anti-spike IgG levels after vaccination were observed between SSc patients and HCs. Anti-spike IgG levels after vaccination were lower in SSc patients with increased CD21low B cells at baseline compared to SSc patients with normal CD21low B cells. A positive correlation was found between IgG levels and naive B cells. A negative linear correlation was shown between IgG levels and IgM-memory, switched-memory, double-negative, and CD21low B cells. Conclusions: SARS-CoV-2 mRNA vaccine response is normal in SSc patients not undergoing immunosuppressive therapy. The normal number of naive B cells is a positive marker of antibody response. The increased percentage of CD21low B cells represents a negative marker of antibody response.

show abstract

Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients

Stai,

Fylaktou,

Kasimatis

et al. 2023

Vaccines

View full text Add to dashboard Cite

Background and Aim: Immune status profile can predict response to vaccination, while lymphocyte phenotypic alterations represent its effectiveness. We prospectively evaluated these parameters in kidney transplant recipients (KTRs) regarding Tozinameran (BNT162b2) vaccination. Method: In this prospective monocenter observational study, 39 adult KTRs, on stable immunosuppression, naïve to COVID-19, with no protective humoral response after two Tozinameran doses, received the third vaccination dose, and, based on their immunity activation, they were classified as responders or non-responders. Humoral and cellular immunities were assessed at predefined time points (T0: 48 h before the first, T1: 48 h prior to the third and T2: three weeks after the third dose). Results: Responders, compared to non-responders, had a higher total and transitional B-lymphocyte count at baseline (96.5 (93) vs. 51 (52)cells/μL, p: 0.045 and 9 (17) vs. 1 (2)cells/μL, p: 0.031, respectively). In the responder group, there was a significant increase, from T0 to T1, in the concentrations of activated CD4+ (from 6.5 (4) to 10.08 (11)cells/μL, p: 0.001) and CD8+ (from 8 (19) to 14.76 (16)cells/μL, p: 0.004) and a drop in CD3+PD1+ T-cells (from 130 (121) to 30.44 (25)cells/μL, p: 0.001), while naïve and transitional B-cells increased from T1 to T2 (from 57.55 (66) to 1149.3 (680)cells/μL, p < 0.001 and from 1.4 (3) to 17.5 (21)cells/μL, p: 0.003). The percentages of memory and marginal zone B-lymphocytes, and activated CD4+, CD8+ and natural killer (NK) T-cells significantly increased, while those of naïve B-cells and CD3+PD1+ T-cells reduced from T0 to T1. Conclusions: Responders and non-responders to the third BNT162b2 dose demonstrated distinct initial immune cell profiles and changes in cellular subpopulation composition following vaccination.

show abstract

Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study

Cited by 4 publications

References 55 publications

The failure to establish herd immunity against SARS-CoV-2

The failure to establish herd immunity against SARS-CoV-2

The Effect of SARS-CoV-2 Vaccination on B-Cell Phenotype in Systemic Sclerosis Patients

Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients

Contact Info

Product

Resources

About